AbbVie to Present at the Wolfe Research Healthcare Conference
Get Alerts ABBV Hot Sheet
Join SI Premium – FREE
NORTH CHICAGO, Ill., Nov. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Wednesday, November 17, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present at 8:30 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-wolfe-research-healthcare-conference-301420573.html
SOURCE AbbVie
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LG ELECTRONICS BEGINS MASS PRODUCTION OF 5G SMART TELEMATICS SOLUTION FOR A PREMIUM EUROPEAN AUTOMAKER
- Bybit Strengthens Security Defences Against Evolving Crypto Threats, Intercepting $700 Million in Potential User Losses
- Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share